Nathan Dowden compensation by year
Entrada Therapeutics Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $354,488 | $378,532 | $440,000 | $456,501 | $480,000 | $499,200 |
| Bonus | $0 | $50,000 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $186,916 | $392,772 | $1,278,263 | $725,952 |
| Option awards | $82,636 | $1,706,565 | $698,873 | $398,384 | $472,615 | $760,363 |
| Non-equity incentive | $124,373 | $176,920 | $202,400 | $224,598 | $216,010 | $224,640 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $0 | $12,200 | $13,200 | $13,800 | $13,342 |
| Total | $561,497 | $2,312,017 | $1,540,389 | $1,485,455 | $2,460,688 | $2,223,497 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Entrada Therapeutics, Inc. DEF 14A filed April 24, 2026, accession 0001689375-26-000021, and prior-year filings.
How this page was built: the Entrada Therapeutics, Inc. filed document, accession 0001689375-26-000021. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 60,800 | $625,024 | — |
| RSU | 60,000 | $616,800 | — |
| PSU | 30,000 | $308,400 | — |
| RSU | 24,825 | $255,201 | — |
| RSU | 7,100 | $72,988 | — |
| RSU | 2,816 | $28,948 | — |
| RSU | 1,408 | $14,474 | — |
| Option | 90,800 | — | $11.94 |
| Option | 28,181 | — | $13.73 |
| Option | 9,406 | — | $15.41 |
| Option | 6,719 | — | $12.25 |
| Option | 4,927 | — | $12.00 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Entrada Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 13 award rows shown.
Insider transactions since the last proxy
4 Form 4 lines since the FY2025 proxy (filed April 24, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-02 | Tax withholding | — | 2,528 | $7.14 | 196,060 |
| 2026-05-04 | Exercise or conversion | 10b5-1 | 15,000 | $1.74 | 213,588 |
| 2026-05-04 | Exercise or conversion derivative | 10b5-1 | 15,000 | $0.00 | 49,831 |
| 2026-05-04 | Sale | 10b5-1 | 15,000 | $15.33 | 198,588 |
The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Entrada Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Dipal Doshi | Chief Executive Officer | $3,837,737 |
| Natarajan Sethuraman | President of Research and Development | $2,254,315 |
| Nathan Dowden · this page | President and Chief Operating Officer | $2,223,497 |
Nathan Dowden's compensation dossier, Entrada Therapeutics
You have read Nathan Dowden's totals and holdings. The dossier adds each equity grant Entrada Therapeutics disclosed for Nathan Dowden and Entrada Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Entrada Therapeutics compensation record
free company briefThis page is one person within Entrada Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Entrada Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Entrada Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.